MedTrace Logo

Treadmill with TENS on Functional Capacity &muscle Oxygenation in PAD Patients

NCT06061211 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-12-12

No results posted yet for this study

Summary

Fifty patients from both sexes with PAD, stage II fontaine will participate in this study. Their ages will be from 40-75 years old. They will be selected from kasr el ainy (faculty of medicine), Cairo University, Giza, Egypt. The patients will be randomly assigned into two equal groups:

Group (A): 25 patients will receive transcutaneous electrical nerve stimulation (TENS) for 45 minutes per session applied on calf muscle, combined with treadmill three days per week for twelve weeks in addition to the routine medical treatment.

Group (B): 25 patients will receive treadmill training for 45 minutes per session, three days per week for twelve weeks in addition to the routine medical treatment

Conditions

  • Peripheral Arterial Disease

Interventions

OTHER

TREADMILL(SIDEA-Germany treadmill ) with TENS

TENS: MH8001 Portable tens 45 min. three times/ week 2-120 HZ 200ms treadmill: SIDEA-Germany treadmill three times/week, 45min, moderate intensity according to claudication pain scale 2MPH(3.5KM/h) 0% grade then increase by 2% every 2min.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Hadeer K Elhashash, AL · faculty of physical therapy

  • Azza A ABDELHADY, Professor · faculty of physical therapy

  • Marwa M Elsayed, lecturer · faculty of physical therapy

  • AHMED A SHAKER, AP · Faculty of medecine

  • ASMAA H HABIB, Lecturer · Faculty of medecine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06061211 on ClinicalTrials.gov